Post only reports a realized gain and excitement over the massive intraday move (+302%). No forward-looking bullish or bearish view is expressed. This is typical day-trading hype around a volatile small-cap biotech; the author is celebrating the casino-like price action, not making a fundamental call. External data shows a tiny market cap (~$3M) and recent share buyback announcement, but the post itself provides no catalyst or thesis. Low confidence due to lack of substantive reasoning.